Market research
ADPT Adaptive Biotechnologies Corp
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 25.0714
- Dividend yield
- Not available
- Beta
- 2.09
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US00650F1093
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 25.0714
- Dividend yield
- Not available
- Beta
- 2.09
About
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ADPT discussion.
5 years, 4 months ago
Adaptive Biotechnologies Corporation is currently in a long term downtrend where the price is trading 18.5% below its 200 day moving average.
From a valuation standpoint, the stock is 95.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 54.8.
Adaptive Biotechnologies Corporation's total revenue rose by 24.7% to $30M since the same quarter in the previous year.
Its net income has dropped by 116.2% to $-45M since the same quarter in the previous year.
Finally, its free cash flow fell by 68.5% to $-49M since the same quarter in the previous year.
Based on the above factors, Adaptive Biotechnologies Corporation gets an overall score of 2/5.